Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 645-651

  Karlberg, M ^a   Öhrling, Katarina ^a   Edler, D ^a   Hallstrom M ^a   Ullen H ^a   Ragnhammar, P ^a  

^a NONE

Author keywords

Adjuvant 5 FU; Colorectal cancer; TS

Indexed keywords

FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 77950535944     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Johnston PG: The Colorectal Cancer Coalition: reflections on the future. Oncologist 11: 970-972, 2006.
2. Benson AB, 3rd: New approaches to the adjuvant therapy of colon cancer. Oncologist 11: 973-980, 2006.
3. Moertel CG, Fleming TR, Macdonald JS et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326, 1995.
4. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004.
5. Johnston PG, Fisher ER, Rockette HE et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
6. Kornmann M, Schwabe W, Sander S et al: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9: 4116-4124, 2003.
7. Aguiar S Jr, Lopes A, Soares FA et al: Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer. Eur J Surg Oncol 31: 863-868, 2005.
8. Yamachika T, Nakanishi H, Inada K et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998.
9. Sugiyama Y, Kato T, Nakazato H et al: Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer. Anticancer Drugs 13: 931-938, 2002.
10. Jensen SA, Vainer B and Sorensen JB: The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 120: 694-701, 2007.
11. Takenoue T, Nagawa H, Matsuda K et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000.
12. Aschele C, Debernardis D, Casazza S et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999.
13. Leichman CG, Lenz HJ, Leichman L et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
14. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y,Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J and Kemeny N: Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21: 406-412, 2003.
15. Edler D, Glimelius B, Hallstrom M et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002.
16. Glimelius B, Dahl O, Cedermark B et al: Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44: 904-912, 2005.
17. Johnston PG, Liang CM, Henry S et al: Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668-6676, 1991.
18. Allegra CJ, Parr AL, Wold LE et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20: 1735-1743, 2002.
19. Allegra CJ, Paik S, Colangelo LH et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21: 241-250, 2003.
20. Horikoshi T, Danenberg KD, Stadibauer TH et al: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52: 108-116, 1992.
21. Knösel T, Emde A, Schlüns K et al: Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer.Neoplasia 77(8): 741-747, 2005.
22. Edler D, Blomgren H, Allegra CJ et al: Immunohistochemical determination of thymidylate synthase in colorectal cancer - methodological studies. Eur J Cancer 33: 2278-2281, 1997.
23. Popat S, Chen Z, Zhao D et al: A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 7: 1810-1817, 2006.
24. Westra JL, Hollema H, Schaapveld M et al: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16: 1646-1653, 2005.
25. Soong R, Shah N, Salto-Tellez M et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 9: 915-919, 2008.
26. Takenoue T, Kitayama J, Takei Y et al: Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 11: 273-279, 2000.
27. Peters GJ, Backus HH, Freemantle S et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002.
28. Derenzini M, Montanaro L, Trere D et al: Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 55: 310-314, 2002.
29. Shankaran V, Wisinski KB, Mulcahy MF et al: The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 12: 87-98, 2008.
30. Duffy MJ, van Dalen A, Haglund C et al: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360, 2007.
31. Locker GY, Hamilton S, Harris J et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.